KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Non-cash Items (2016 - 2019)

Historic Non-cash Items for Supernus Pharmaceuticals (SUPN) over the last 9 years, with Q1 2019 value amounting to $2.6 million.

  • Supernus Pharmaceuticals' Non-cash Items rose 706.91% to $2.6 million in Q1 2019 from the same period last year, while for Mar 2019 it was $2.6 million, marking a year-over-year increase of 706.91%. This contributed to the annual value of $57.2 million for FY2018, which is 4727.24% down from last year.
  • Per Supernus Pharmaceuticals' latest filing, its Non-cash Items stood at $2.6 million for Q1 2019, which was up 706.91% from $57.2 million recorded in Q4 2018.
  • Supernus Pharmaceuticals' 5-year Non-cash Items high stood at $108.5 million for Q4 2017, and its period low was $856008.0 during Q2 2015.
  • For the 5-year period, Supernus Pharmaceuticals' Non-cash Items averaged around $15.0 million, with its median value being $2.0 million (2017).
  • Its Non-cash Items has fluctuated over the past 5 years, first soared by 53000.0% in 2015, then plummeted by 4727.24% in 2018.
  • Quarter analysis of 5 years shows Supernus Pharmaceuticals' Non-cash Items stood at $12.6 million in 2015, then soared by 333.91% to $54.7 million in 2016, then skyrocketed by 98.49% to $108.5 million in 2017, then plummeted by 47.27% to $57.2 million in 2018, then crashed by 95.45% to $2.6 million in 2019.
  • Its Non-cash Items stands at $2.6 million for Q1 2019, versus $57.2 million for Q4 2018 and $1.9 million for Q3 2018.